NEWARK, Del. — According to Future Market Insights (FMI), the global critical limb ischemia treatment market is valued at USD 4.9 billion in 2026 and is projected to reach USD 9.8 billion by 2036, expanding at a 7.2% CAGR during the 2026–2036 forecast period. Clinical demand for revascularization remains a key market driver as healthcare providers address severe peripheral artery disease, ischemic tissue loss, and diabetic complications requiring coordinated limb-salvage pathways. The National Vascular Registry reported 16,618 lower-limb revascularizations across UK hospitals in November 2025, based on procedures completed during 2024.
Treatment decisions vary according to lesion location, calcification, wound status, and surgical risk. The American Heart Association noted in February 2025 that peripheral artery disease pain and clinical risk profiles vary across the disease spectrum. FMI identifies the treatment pathway as extending beyond revascularization to include wound management, follow-up, and tissue-recovery monitoring.
???? Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-34370
Global Segment Leaders
- Endovascular Therapy — 41.0% share: Endovascular therapy leads the treatment-type segment in 2026, supported by catheter-based access for selected patients and established hospital revascularization capabilities.
- Peripheral Artery Disease — 44.0% share: Peripheral artery disease represents the leading application segment, reflecting its direct connection with ischemic rest pain and tissue loss.
- Hospitals — 46.0% share: Hospitals account for the largest end-user share because they combine multidisciplinary vascular teams, intervention infrastructure, imaging capabilities, and wound-management services.
- Direct Sales — 49.0% share: Direct sales lead the distribution channel category, supported by procedural training, manufacturer assistance, inventory management, and clinical support for complex peripheral interventions.
- Angioplasty Balloons — 37.0% share: Angioplasty balloons represent the leading device-type category in 2026 because of their broad use in vessel-opening procedures and availability across different lesion-specific configurations.
Regional Context
- Europe includes the UK and Germany among the profiled markets. The UK is forecast to expand at 8.9% CAGR, supported by national vascular audit visibility and established endovascular networks. Germany is projected to grow at 5.9%, with specialist capacity and formal evidence assessment shaping access to treatment technologies.
- North America includes Canada and the USA. Canada's market is projected to grow at 8.4%, with complex vascular care concentrated in provincial tertiary centers. The USA is forecast at 6.9%, supported by established intervention infrastructure and defined coverage requirements for eligible procedures.
- Latin America is represented by Brazil among the detailed country forecasts. Brazil is projected to expand at 7.8% CAGR, with diabetic-foot prevention and primary-care screening creating additional routes for vascular referral. Import costs and uneven specialist availability remain constraints outside metropolitan hospital networks.
- East Asia and Oceania show different adoption conditions. Japan is forecast at 7.4% CAGR, supported by regulated device introduction and specialist vascular care, while Australia is projected at 5.3% amid geographically concentrated advanced vascular services.
FMI's full assessment covers North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa, with more than 30 additional countries covered beyond the seven countries receiving detailed CAGR analysis.
???? Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-34370
Drivers, Restraints and Opportunities
Diabetes-related vascular disease remains a central growth driver. FMI cites National Vascular Registry data showing diabetes among 50.6% of lower-limb revascularization patients in 2024. Poor perfusion and impaired wound healing create demand for treatment pathways connecting vascular intervention with wound care and follow-up.
Delayed referral and complex calcification remain key restraints. The National Vascular Registry reported that 49% of emergency CLTI patients received revascularization within five days during 2024, with a six-day median interval across emergency cases. These figures indicate that device availability alone does not remove scheduling and referral delays.
Integrated vascular and diabetic-foot pathways present an opportunity for treatment providers and device manufacturers. Brazil's Ministry of Health published a primary-care methodology in September 2025 incorporating foot evaluation into longitudinal diabetes management, creating a route for earlier wound recognition and specialist vascular referral.
Competitive Landscape
The competitive landscape includes Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Becton, Dickinson and Company, Cook Medical LLC, Cordis, and Koninklijke Philips N.V. The companies compete through peripheral revascularization portfolios, lesion-preparation technologies, thrombectomy, drug-eluting devices, intravascular imaging, and procedural education.
Abbott, Boston Scientific, and Medtronic provide broad peripheral revascularization portfolios, while Terumo, Becton Dickinson, and Cordis focus on access platforms and lesion-specific peripheral technologies. Cook Medical contributes drug-eluting stent capabilities, while Philips supports arterial imaging and procedural education.
Key Recent Developments
- April 2025: Boston Scientific completed its acquisition of Bolt Medical, adding an intravascular lithotripsy platform under development for coronary and peripheral artery disease. The transaction expanded its calcium-modification pipeline for difficult calcified lesions.
- August 2025: Abbott received CE Mark for the Esprit BTK everolimus-eluting resorbable scaffold for severe below-the-knee peripheral artery disease. The device is designed to restore blood flow without leaving a permanent metal implant.
- October 2025: Becton, Dickinson and Company enrolled the first patient in the XTRACT registry for its Rotarex catheter system. The registry is expected to include as many as 600 patients across 100 U.S. clinical sites.
- April 2026: Cordis launched the SELUTION SLR PTA drug-eluting balloon in Japan for peripheral artery disease treatment, adding a sirolimus-eluting balloon to the country's regulated peripheral intervention market.
Access Full Report: https://www.futuremarketinsights.com/reports/critical-limb-ischemia-treatment-market
Analyst Perspective
“Critical limb ischemia programs create value through timely referral and durable tissue recovery rather than procedure volume alone. Hospitals need device evidence beside wound-care capacity and coordinated follow-up across the complete salvage pathway. Companies earn repeat use through technologies that fit difficult anatomy and support measurable healing without adding unnecessary inventory or training burdens.”
— Anurag Sharma, Principal Analyst, Future Market Insights
About Future Market Insights
Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, medical devices, and pharmaceuticals.
Related Reports:
- Endoscopic Service And Support Market - https://www.futuremarketinsights.com/reports/endoscopic-service-and-support-market
- Advanced Implantable Electrode Neurotechnology Market - https://www.futuremarketinsights.com/reports/advanced-implantable-electrode-neurotechnology-market
- AI-Accelerated Nonclinical Drug Testing Market - https://www.futuremarketinsights.com/reports/ai-accelerated-nonclinical-drug-testing-market
About Future Market Insights (FMI)
Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.
For Press & Corporate Inquiries
Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com
Comments (0)